Immune thrombocytopenia (ITP) is a disorder of increased platelet destruction and reduced platelet production and is associated with an increased bleeding risk and a compromised quality of life.

Current second-line treatments for immune thrombocytopenia (ITP) require long-term administration. Ianalumab, a monoclonal antibody targeting B cells, is being assessed as a short-course second-line ...

Scientists have created a new atlas of plant cells during immune response, in turn discovering a new rare cell state, called Primary IMmunE Responder (PRIMER), that acts as an immune response hub to ...